Epizyme

• NCT05618366

  Collaborator, Phase 1, Terminated, 3 people, 16 Nov 2022

• NCT05205252

  Phase 1/2, Withdrawn, 0 people, 25 Jan 2022

• NCT04204941

  Phase 1, Terminated, 25 people, 19 Dec 2019

• NCT04179864

  Phase 1/2, Terminated, 102 people, 27 Nov 2019

• NCT02889523

  Collaborator, Phase 1/2, Active, not recruiting, 214 people, 5 Sept 2016

• NCT01897571

  Phase 1/2, Completed, 400 people, 12 Jul 2013

• Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomas

  Fees or honoraria, 24 Oct 2025

Sources: pubmed.ncbi.nlm.nih.gov